CMS
CMS on Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, and on Wednesday released guidance on the new Medicare drug price negotiation program—including its intersection with 340B.

CMS Announces First Drugs Subject to Medicare Inflation Rebates, Issues Guidance Addressing 340B and Medicare Negotiated Drug Prices

The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, a list that includes AbbVie’s blockbuster arthritis drug Humira, which generated $5.6 billion in global sales last year. A number of Pfizer products, including blood thinner Fragmin and leukemia drug Nipent are also among the first drugs slated for rebates.

CMS’ Medicare Prescription Drug Inflation Rebate Program (MPDIRP) targets prescription drug products whose prices have risen faster than the rate of inflation.

The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer